Home » Myriad Completes Acquisition of Sividon Diagnostics
Myriad Completes Acquisition of Sividon Diagnostics
Myriad Genetics has finalized its acquisition of Sividon Diagnostics, a breast cancer prognostic company, for approximately $39 million upfront.
Under the deal, Myriad will also gain $17 million in potential milestones. — Anisa Jibrell
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May